SIRION Biotech launches operation in USA
Press Release | SIRION Biotech GmbH
APRIL 30, 2015
Martinsried, Germany: – Leading viral vector specialist SIRION Biotech expands its North American presence by opening a sales office and soon a laboratory in Boston, USA.
The new American outlet will give American clients quicker and more immediate access to SIRION’s world-leading adenovirus, lentivirus and AAV technology platforms.
Viral vector technologies for the world
The Massachusetts office will join other SIRION subsidiaries South Korea, Israel and Japan as part of a pattern of impressive and sustained growth for SIRION, which is leading a wave of soaring interest and uptake of viral vector technologies. The company’s revenues have been increasing at around 40 per cent annually since it began operating in 2007.
SIRION Biotech has established itself as the leading viral vector technology provider in Europe with more than 500 single projects and more than 150 repeat clients in recent years. With its constant growth in the preclinical sector and a successful track record worldwide, the company decided the time had come to make a move closer to the US science community, enabling easier access to its advanced technology platforms.
Advanced viral platforms
“It’s fair to say that sales in the USA have lagged behind compared to what we’re experiencing worldwide,” said Dr. Carl J. Christel, SIRION’s Senior Manager for Sales & Marketing in North America.
“We experience a general reluctance to make contact with our HQ in Europe and believe that having direct access to SIRION in the US will make a huge difference,” Christel said.
“It’s not just a psychological thing – we also think that with the new Boston operation we will be able to provide even quicker and more focused services to our American customers,” added Dr. Christel.
“We’ll be offering exactly the same range of high quality virus technologies that we do in Munich – but now we’ll just be a bit nearer and easier to talk to,” he said.
About SIRION Biotech
SIRION BIOTECH is Europe’s leading commercial supplier of viral vectors used for genetic research, target validation, gene therapy and vaccination studies.
In business since 2007, SIRION’s mission has been to change the paradigm for viral vector supplies. It has the ability to develop and supply all common viral vector types (adenovirus, lentivirus and AAV) available within a matter of weeks at titers required for preclinical research and development.
The company completes these platforms with a full range of virus related services, ranging from the transformational RNAiONE™ knockdown validation platform to virus driven cell modeling.
Dr. Carl J. Christel, Senior Manager, Sales & Marketing, SIRION Biotech Inc., USA
Tel: +1 857 284 1844